Room for improvement

Immunizations for patients with monoclonal B-cell lymphocytosis or chronic lymphocytic leukemia

Jennifer A. Whitaker, Tait D. Shanafelt, Gregory A. Poland, Neil Elliot Kay

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Infection is the cause of death in 30% to 50% of patients with chronic lymphocytic leukemia (CLL). A major strategy to decrease infection risk is vaccination. However, vaccine response rates in patients with CLL are typically insufficient. Recent studies have demonstrated that individuals with clinical monoclonal B-cell lymphocytosis (MBL), the precursor to CLL, also have an increased risk of infection and thus could benefit from vaccines. However, there are no data on vaccine responses in the MBL population. This article reviews the immunodeficiency of CLL and MBL, discusses the recommended vaccines and data on vaccine immunogenicity in patients with CLL, and outlines the need to develop more effective vaccine strategies in this population of patients at high risk for infection.

Original languageEnglish (US)
Pages (from-to)440-450
Number of pages11
JournalClinical Advances in Hematology and Oncology
Volume12
Issue number7
StatePublished - 2014

Fingerprint

Lymphocytosis
B-Cell Chronic Lymphocytic Leukemia
Immunization
Vaccines
Infection
B-Lymphoid Precursor Cells
Population
Cause of Death
Vaccination
B-Lymphocytes

Keywords

  • Chronic Lymphocytic Leukemia (CLL)
  • Immunization
  • Monoclonal B-cell Lymphocytosis (MBL)
  • Vaccine

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Room for improvement : Immunizations for patients with monoclonal B-cell lymphocytosis or chronic lymphocytic leukemia. / Whitaker, Jennifer A.; Shanafelt, Tait D.; Poland, Gregory A.; Kay, Neil Elliot.

In: Clinical Advances in Hematology and Oncology, Vol. 12, No. 7, 2014, p. 440-450.

Research output: Contribution to journalArticle

@article{e9fd9561882144caa659a56d43fb3128,
title = "Room for improvement: Immunizations for patients with monoclonal B-cell lymphocytosis or chronic lymphocytic leukemia",
abstract = "Infection is the cause of death in 30{\%} to 50{\%} of patients with chronic lymphocytic leukemia (CLL). A major strategy to decrease infection risk is vaccination. However, vaccine response rates in patients with CLL are typically insufficient. Recent studies have demonstrated that individuals with clinical monoclonal B-cell lymphocytosis (MBL), the precursor to CLL, also have an increased risk of infection and thus could benefit from vaccines. However, there are no data on vaccine responses in the MBL population. This article reviews the immunodeficiency of CLL and MBL, discusses the recommended vaccines and data on vaccine immunogenicity in patients with CLL, and outlines the need to develop more effective vaccine strategies in this population of patients at high risk for infection.",
keywords = "Chronic Lymphocytic Leukemia (CLL), Immunization, Monoclonal B-cell Lymphocytosis (MBL), Vaccine",
author = "Whitaker, {Jennifer A.} and Shanafelt, {Tait D.} and Poland, {Gregory A.} and Kay, {Neil Elliot}",
year = "2014",
language = "English (US)",
volume = "12",
pages = "440--450",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "7",

}

TY - JOUR

T1 - Room for improvement

T2 - Immunizations for patients with monoclonal B-cell lymphocytosis or chronic lymphocytic leukemia

AU - Whitaker, Jennifer A.

AU - Shanafelt, Tait D.

AU - Poland, Gregory A.

AU - Kay, Neil Elliot

PY - 2014

Y1 - 2014

N2 - Infection is the cause of death in 30% to 50% of patients with chronic lymphocytic leukemia (CLL). A major strategy to decrease infection risk is vaccination. However, vaccine response rates in patients with CLL are typically insufficient. Recent studies have demonstrated that individuals with clinical monoclonal B-cell lymphocytosis (MBL), the precursor to CLL, also have an increased risk of infection and thus could benefit from vaccines. However, there are no data on vaccine responses in the MBL population. This article reviews the immunodeficiency of CLL and MBL, discusses the recommended vaccines and data on vaccine immunogenicity in patients with CLL, and outlines the need to develop more effective vaccine strategies in this population of patients at high risk for infection.

AB - Infection is the cause of death in 30% to 50% of patients with chronic lymphocytic leukemia (CLL). A major strategy to decrease infection risk is vaccination. However, vaccine response rates in patients with CLL are typically insufficient. Recent studies have demonstrated that individuals with clinical monoclonal B-cell lymphocytosis (MBL), the precursor to CLL, also have an increased risk of infection and thus could benefit from vaccines. However, there are no data on vaccine responses in the MBL population. This article reviews the immunodeficiency of CLL and MBL, discusses the recommended vaccines and data on vaccine immunogenicity in patients with CLL, and outlines the need to develop more effective vaccine strategies in this population of patients at high risk for infection.

KW - Chronic Lymphocytic Leukemia (CLL)

KW - Immunization

KW - Monoclonal B-cell Lymphocytosis (MBL)

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84905193390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905193390&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 440

EP - 450

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 7

ER -